Pemafibrate is a next-generation selective PPARalpha modulator (SPPARMalpha) developed to lower triglycerides and improve lipid profiles with a more favourable hepatic and renal safety margin than classical fibrates. As a relatively recent addition to lipid-lowering pharmacotherapy, robust analytical reference material is essential for emerging generic development. Simson Pharma offers the Pemafibrate reference standard together with characterised impurities for method validation.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Pemafibrate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.